Business
Advicenne Has Successfully Renewed the Marketing Authorization of Sibnayal® in European Union
PARIS, January 12, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains the renewal of its Marketing Authorization (MA) for Sibnayal® (fixed combination of potassium citrate and potassium bicarbonate) for the treatment of distal Renal Tubular Acidosis (dRTA) in the European Union.
About this update from Advicenne Sa
[{"type":"text","content":"PARIS, January 12, 2026--(BUSINESS WIRE)--Regulatory News:","length":58,"tagName":"p"},{"type":"text","content":"Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains the renewal of its Marketing Authorization (MA) for Sibnayal® (fixed combination of potassium citrate and potassium bicarbonate) for the treatment of distal Renal Tubular Acidosis (dRTA) in the European Union.","length":419,"tagName":"p"},{"type":"text","content":"The European Medicines Agency (EMA) has renewed the marketing authorization for Sibnayal® starting in January 2026. This renewal, which is mandatory five years after the initial issuance, definitively validates the marketing authorization.","length":239,"tagName":"p"},{"type":"text","content":"It marks a major milestone for the continued commercial development of Sibnayal® in Europe. It is part of a busy regulatory program, with marketing authorization obtained in the Kingdom of Saudi Arabia in July 2025 and, more recently, the filing of a registration application with the US Food & Drug Administration.","length":319,"tagName":"p"},{"type":"text","content":"* *","length":3,"tagName":"p","attribs":{}},{"type":"text","content":"*","length":1,"tagName":"p","attribs":{}},{"type":"text","content":"About Advicenne","length":15,"tagName":"p"},{"type":"text","content":"Advicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022.","length":599,"tagName":"p"},{"type":"text","content":"For additional information, see: https://advicenne.com/.","length":56,"tagName":"p"},{"type":"text","content":"Disclaimer","length":10,"tagName":"p"},{"type":"text","content":"This press release contains certain forward-looking statements concerning...